Iguana Healthcare Management Raised Cymabay Therapeutics (CBAY) Stake By $1.16 Million; Boston Beer Co (SAM) Has 1.15 Sentiment

February 23, 2018 - By Marie Mckinney

The Boston Beer Company, Inc. produces and sells alcohol beverages primarily in the United States. The company has market cap of $1.98 billion. The Company’s flagship beer is Samuel Adams Boston Lager. It has a 23.38 P/E ratio. The firm sells approximately 60 beers under the Samuel Adams and the Sam Adams brands; 20 hard cider beverages under the Angry Orchard brand; 13 flavored malt beverages under the Twisted Tea brand; and 4 hard seltzer beverages under the Truly Spiked & Sparkling brand name, as well as approximately 40 beers under A&S Brewing trade name.

Iguana Healthcare Management Llc increased Cymabay Therapeutics Inc (CBAY) stake by 138.1% reported in 2017Q3 SEC filing. Iguana Healthcare Management Llc acquired 145,000 shares as Cymabay Therapeutics Inc (CBAY)’s stock rose 21.05%. The Iguana Healthcare Management Llc holds 250,000 shares with $2.02M value, up from 105,000 last quarter. Cymabay Therapeutics Inc now has $804.53 million valuation. The stock decreased 0.55% or $0.08 during the last trading session, reaching $14.51. About 397,682 shares traded. Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has risen 69.26% since February 23, 2017 and is uptrending. It has outperformed by 52.56% the S&P500.

Among 7 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc had 21 analyst reports since July 21, 2015 according to SRatingsIntel. Oppenheimer maintained the shares of CBAY in report on Wednesday, January 10 with “Buy” rating. The company was initiated on Tuesday, September 19 by Cantor Fitzgerald. On Monday, January 30 the stock rating was upgraded by H.C. Wainwright to “Buy”. The rating was initiated by Piper Jaffray with “Overweight” on Tuesday, July 21. The firm earned “Buy” rating on Monday, July 17 by H.C. Wainwright. The firm earned “Buy” rating on Friday, July 1 by Roth Capital. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by Cantor Fitzgerald on Wednesday, October 25. The firm earned “Neutral” rating on Wednesday, January 4 by H.C. Wainwright. The rating was maintained by Leerink Swann with “Buy” on Tuesday, November 28. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by Piper Jaffray on Monday, September 11.

Ratings analysis reveals 0 of Boston Beer Co’s analysts are positive. Out of 3 Wall Street analysts rating Boston Beer Co, 0 give it “Buy”, 2 “Sell” rating, while 1 recommend “Hold”. SAM was included in 3 notes of analysts from September 16, 2016. The company was maintained on Friday, October 21 by RBC Capital Markets. Berenberg downgraded the stock to “Sell” rating in Friday, October 14 report. The stock of The Boston Beer Company, Inc. (NYSE:SAM) earned “Underperform” rating by Credit Suisse on Friday, September 16.

The stock increased 2.07% or $3.45 during the last trading session, reaching $170.35. About 142,237 shares traded. The Boston Beer Company, Inc. (SAM) has declined 3.11% since February 23, 2017 and is downtrending. It has underperformed by 19.81% the S&P500.

Rk Asset Management Llc holds 8.86% of its portfolio in The Boston Beer Company, Inc. for 65,126 shares. Vgi Partners Pty Ltd owns 229,298 shares or 7.25% of their US portfolio. Moreover, Manikay Partners Llc has 2.04% invested in the company for 210,000 shares. The Maryland-based Profit Investment Management Llc has invested 1.87% in the stock. Harvest Capital Strategies Llc, a California-based fund reported 50,000 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.